Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MT-7117 in Erythropoietic Protoporphyria
NCT03520036Phase 2Completed
- Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Start
- Jul 2018
- Primary completion
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of dersimelagon in erythropoietic protoporphyria (EPP), sponsored by Mitsubishi Tanabe Pharma Corporation. Started Jul 2018; status: completed.
02
Drugs
dersimelagon
03
Conditions
erythropoietic protoporphyria (EPP)
Beyond the preview
Go deeper on NCT03520036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03520036.